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A B S T R A C T
Pomegranate peel contains high levels of various phytochemicals. We evaluated the effects of pomegranate peel
extract (PoPEx) consumption on plasma lipid profile, fatty acids (FA) level and blood pressure (BP) in patients
with diabetes mellitus type 2 (DMT2). Thirty-seven subjects were recruited in this double blind, placebo con-
trolled randomized trial. The study group (n = 19) received over 8 week’s capsules containing PoPEx twice a
daily, while the placebo group received placebo. Treatment with PoPEx induced a significant lowering of both
systolic and diastolic BP. The plasma levels of triglycerides, low-density lipoprotein cholesterol/high-density
lipoprotein cholesterol ratio (LDL-C/HDL-C), and HbA1c were significantly decreased, while the level of HDL-C
was significantly increased, compared with placebo intake. Moreover, the PoPEX treatment significantly im-
proved the plasma lipids fatty acids content. It is concluded that consumption of PoPEx in DMT2 subject had
favourable effects on some metabolic parameters, BP, lipid profile and plasma lipid FA composition.
1. Introduction
Diabetes mellitus1 (DMT2) is a serious public health problem. Ac-
cording to the 2017 International Diabetes Federation report, ap-
proximately 425 million adults (range 20–79 years) were living with
diabetes, and by year 2045 it will rise to 629 million globally. The
proportion of people suffering from DMT2 is increasing in most coun-
tries, but 79% of adults with diabetes were living in low- and middle-
income countries (International Diabetes Federation, 2017). The epi-
demics of obesity and sedentary lifestyle have contributed to the
prevalence of diabetes and high blood pressure2 (BP) (Sowers, 2013).
Obesity is linked to insulin resistance and is one of the main char-
acteristics of the DMT2 (Boden, 1997); Lewis, Carpentier, Adeli, &
Giacca, 2002). Diabetes is associated with hypertension and dyslipi-
demia, which lead to increased risk of cardiovascular complications
such as angina, coronary artery diseases, myocardial infarction, stroke,
peripheral artery disease, and congestive heart failure (American
Diabetes Association, 2019). Adults suffering from diabetes have two to
three times greater frequency of cardiovascular disease3 (CVD) in
comparison to those without diabetes (Sarwar et al., 2010).
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Most of the DMT2 patients have dyslipidemia with increased levels
of low-density lipoprotein cholesterol4 (LDL-C) and triglycerides5 (TG),
and low levels of high-density lipoprotein cholesterol6 (HDL-C)
(Parhofer, 2015; Wu & Parhofer, 2014). Changes in lipid metabolism
are associated with changes in fatty acids7 (FA) composition of blood
lipids. Patients with diabetes usually have higher levels of saturated
fatty acids8 (SFA), in particular palmitic acid (16:0), as well as FA that
may derive from palmitic acid during de novo lipogenesis, including
palmitoleic acid (16:1n–7) and stearic acid (18:0) (Lemaitre et al.,
2015). These FA have been associated with insulin resistance and dia-
betes risk in several epidemiologic studies (Kröger et al., 2011). Status
of n-3 polyunsaturated fatty acids9 (PUFA) is inversely associated with
diabetes, mostly docosahexaenoic acid10 (DHA, 22:6n-3) although a
novel study reported that this relation is sex-dependent (Abbott et al.,
2019). Hyperglycemia activates production of reactive oxygen species11
(ROS) and presents a condition of oxidative stress and inflammation,
which is linked to a high production of adhesion molecules and
proinflammatory cytokines (Preedy, 2016). Therefore, diabetes is a
chronic pro-inflammatory condition which decreases antioxidative po-
tential of cells making them easily damaged (Preedy, 2016).
There is no absolute cure for diabetes. It can be managed by com-
bination of various approaches, such as antidiabetic medications,
physical activity, healthy diet, and herbal remedies (Banihani, Swedan,
& Alguraan, 2013; Shishehbor et al., 2016). Growing evidence from
animal studies supports the anti-diabetic properties of some dietary
polyphenols, suggesting that dietary polyphenols could be one dietary
therapy for the prevention and management of DMT2. Studies have
shown that polyphenols can improve conditions of glucose and lipid
metabolic disorder, and their anti-inflammatory effects have been de-
termined (Shishehbor et al., 2016). Pomegranates contain high levels of
various phytochemicals such as polyphenols, fatty acids, amino acids,
tocopherols, sterols, terpenoids, alkaloids that have therapeutic effects
and are used either for their anti-inflammatory properties, as anti-
oxidants, or for their antineoplastic, hypoglycemic, lipid-lowering or
antimicrobial effects (Viuda-Martos, Fernandez-Lopez, & Perez-Alvarez,
2010). Fractions of various pomegranate parts show potential for
treating numerous illnesses and disorders including cardiovascular
diseases and diabetes mellitus. It is shown that pomegranate extract
antagonizes harmful effects of prooxidants and reduces oxidative stress
and lipid peroxidation (Esmaillzadeh, Tahbaz, Gaieni, Alavi-Majd, &
Azadbakht, 2004; Fenercioglu, Saler, Genc, Sabuncu, & Altuntas, 2010;
Viuda-Martos et al., 2010). Besides its antioxidative effects, pome-
granate juice reduces TG, LDL-C, increases HDL-C and lowers blood
pressure (Vučić, Grabež, Trchounian, & Arsić, 2019; Esmaillzadeh et al.,
2004; Fenercioglu et al., 2010). Nonedible part of the pomegranate fruit
is its peel, which makes 40% of the total mass of the fruit, and is usually
considered as a waste (Çam, Içyer, & Erdoǧan, 2014). However, it
contains phytochemicals that are medically and nutritionally important
(Singh, Chidambara Murthy, & Jayaprakasha, 2002). Almost 48 phenol
components (flavonoids, condensed tannins and hydrolysable tannins)
have been detected in pomegrante peel and other parts of pomegranate
fruit (Akhtar, Ismail, Fraternale, & Sestili, 2015; Singh et al., 2002).
Although the beneficial effects of pomegranate juice on various para-
meters of DMT2 in experimental and clinical studies have been well
documented (Atrahimovich, Samson, Khattib, Vaya, & Khatib, 2018;
Aviram & Dornfeld, 2001; Banihani et al., 2013; Rosenblat, Hayek, &
Aviram, 2006) the effect of pomegranate peel extract12 (PoPEx) has not
been properly examined in clinical trials so far.
The aim of this study was to evaluate the effects of pomegranate
peel extract consumption on blood pressure, plasma glycemic and lipid
profile, and fatty acids in patients with diabetes mellitus type 2.
2. Material and methods
2.1. Study population
This study was a randomized, double blind, placebo-controlled
clinical trial in patients with type 2 diabetes mellitus. The patients were
recruited at the Endocrinology Department of the University Clinical
Centre of Republic of Srpska, Banja Luka, Republic of Srpska, Bosnia &
Herzegovina. All participants were in the age range of 40–65 years, had
a body mass index13 (BMI) ≥ 25 kg/m2, HbA1C ≥ 6.5% and were
treated with oral hypoglycaemic agent, metformin at least one year
before beginning of the study, in recommended daily doses. Partici-
pants not considered for the study were those with chronic kidney,
liver, or inflammatory diseases; those who were taking hormone re-
placement therapy, or antioxidant supplements; or were on insulin
treatment or anti-inflammatory medications.
2.2. Ethical considerations
All participants who expressed an interest to participate in the study
signed an informed consent. During the recruitment phase, participants
were informed of the study purpose and protocol, risks/benefits related
to their participation, proposed testing, and the study time course. The
study protocol was approved by the Ethics Committee of the Faculty of
Medicine No.:01-9-604-2/17, University of Banja Luka and was con-
ducted in accordance with the Declaration of Helsinki.
2.3. Study design
Thirty-seven patients were randomly allocated into two groups,
blinded to both participants and researchers. The study group (PoPEx
group; n = 19) received capsules containing pomegranate peel extract
(250 mg) twice a day for period of 8 weeks, while the placebo group
(n = 18) received visually identical capsules containing placebo
(250 mg). Participants were asked not to change their dietary habits,
physical activities, and medication regimens during the study period.
Each participant was provided with a fixed number of capsules needed
for the course of treatment and they were contacted by the principal
investigator on a weekly basis to verify if they have taken capsules
regularly.
2.4. Pomegranate peel extract
Method of triple percolation, using 70% ethanol as a solvent, was
used for the preparation of pomegranate peel extract. The solvent was
evaporated to dryness using vacuum oven in order to obtain a dry ex-
tract. Phenolic compounds, as the most responsible for the biological
activity of the pomegranate peel, were quantified in the extract. Base on
high pressure liquid chromatography14 (HPLC) methodology, the ob-
tained dry extract contained punicalagin 69.67 ± 0.72 mg/g, puni-
calin 30.41 ± 0.11 mg/g, ellagic acid 23.83 ± 0.07 mg/g and gallic
acid 10.46 ± 0.04 mg/g as the main phenolic compounds. HPLC
chromatogram is presented on Fig. 1. Toatal tannins were detected
spectrophotometrically according to European Pharmacopoeia 8.0
(Council of Europe, 2013) and the amount was 11.8% which is in
4 LDL-C, low-density lipoprotein cholesterol.
5 TG, triglycerides.
6 HDL-C, high-density lipoprotein cholesterol.
7 FA, fatty acids.
8 SFA, saturated fatty acids.
9 PUFA, polyunsaturated fatty acids.
10 DHA, docosahexaenoic acid.
11 ROS, reactive oxygen species.
12 PoPEx, pomegranate peel extract.
13 BMI, body mass index.
14 HPLC, high pressure liquid chromatography.
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accordance with WHO monograph (WHO, 2009). Each capsule con-
tained 250 mg of the dry extract. Placebo capsule contained only ex-
cipients, lactose, starch and magnesium stearate. The energy value of
pomegranate capsules and placebo capsules was less than 50 kJ/12 kcal
per 100 g of product.
2.5. Anthropometric and clinical variables
Anthropometric measurements were taken at the beginning and at
the end of intervention period using standard techniques. All mea-
surements were made by trained personnel in the morning with the
subject wearing only underwear. Height was determined using a height
meter with an accuracy of 1 mm. Waist circumference (WC)15 was
measured with a non-stretchable tape. Weight was measured by stan-
dard scale with an accuracy of 100 g. Body composition (fat mass and
fat-free mass) was determined using a Tanita bioelectrical impedance
analyser (Tanita MC-780MA; Tanita Corporation, Tokyo, Japan). Body
mass index was calculated according to the following formula: [weight
(kg)/height (m)2]. Blood pressure was measured on the right arm of
patient in seating position using a digital sphygmomanometer (Omron
Intell Sense, HEM-907XL, Omron Company, Kyoto, Japan) with accu-
racy of ± 5 mmHg. Three consecutive measurements were taken at 5-
min intervals, and the mean values were calculated.
2.6. Energy intake
To estimate energy intake and account for any changes during the
intervention period, which could influence the results, a 3 days’ food
diary was collected at baseline and at the last 3 days of the week 8.
Energy intake was generated using the Serbian Food Composition
Database, harmonized with EuroFIR standards and embedded in
EuroFIR Food Platform and Balkan food platform (Gurinović et al.,
2016). Food recording support and training including guidance on
portion sizes and household measures, were provided by the researcher.
2.7. Biochemical analysis
Blood samples were collected after 12–14 h overnight fasting at
baseline, and at the end of study protocol. The 5 mL of plasma samples
were stored at −80 °C until analysis. Total cholesterol16 (TC), LDL-C,
HDL-C, TG, HbA1C and glucose were determined using standard bio-
chemical methods at Cobas 6000 analyzer (Roche Diagnostics, Man-
nheim, Germany). Serum insulin concentration was measured using the
ADVIA Centaur XPT immunoassay analyzer (Siemens Healthineers,
Tarrytown, NY, USA.).
Insulin resistance was calculated with homeostatic model of insulin
resistance17 (HOMA-IR index), and insulin sensitivity was calculated









log fasting insulin μ log fasting glycemia1/[ ( IU/mL) (mg/dL
mmol/L 18.182)],
The method of Glaser, Demmelmair, and Koletzko (2010) was used
for determining FA profile in plasma total lipids. The method was
slightly modified, as follows: 100 mL of plasma is mixed with 1.5 mL of
3 M HCL in MetOH. This mixture was heated on 85 °C for 45 min. After
the mixture was cooled down to room temperature, 1 mL of hexane was
added, vortexed for 30 s and centrifuged on 1800g for 10 min. Hexane
layer was separated and evaporated to dry in the nitrogen stream. The
sample was dissolved in 10 µL of hexane and 1 µL of the solution was
injected in gas chromatograph, equipped with capillary column
RESTEK Rtc 2330, 60 m, 0.25 mm, 0.2 mm. Temperature was set on
140–210 °C for 3 min. Individual FA were identified in comparison to
the retention times of FA methyl esters commercial standards PUFA-2
(Supelco Inc., Bellefonte, Pennsylvania, USA). The results are presented
as percentage of total FA composition.
Fig. 1. HPLC chromatogram (λ = 260 nm) of dry pomegranate peel extract. Peak numbers as follows: 1, gallic acid; 2, punicalin; 3, punicalagin α + β; 4, ellagic
acid.
15 WC, waist circumference.
16 TC, total cholesterol.
17 HOMA-IR, homeostatic model of insulin resistance.
18 QUICKi, quantative insulin sensitivity check index.
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Index of lipid peroxidation was estimated in the plasma samples by
measuring Thiobarbituric acid reactive species19 (TBARS) according to
the method of Ohkawa, Ohishi, and Yagi (1979). Thiobarbituric acid
(1% in 0.05 M NaOH) was incubated with the plasma sample at 100 °C
for 15 min and measured at 530 nm. Distilled water was used as a blank
probe.
2.8. Statistical analyzes
Data were analyzed using IBM SPSS 20 (Chicago, IL, USA), con-
sidering p < 0.05 as significant. Data obtained from intervention study
are expressed as mean ± standard deviation. Normality of variables
distribution was assessed by Shapiro-Wilk’s test. After checking data
distribution, the appropriate parametric or non-parametric test was
used. For comparisons between groups at baseline, the following sta-
tistical tests were used: Student’s t test and Mann-Whitney U test.
Furthermore, for analysis of differences in the outcome variables were
performed paired sample t-test or Wilcoxon Signed Rang test.
3. Results
3.1. Study population and baseline characteristics
The study was performed between June and November 2018. All
recruited patients (20 females and 17 males) completed the study.
There were no gender differences between the groups; study group
(n = 19) with 10 females’ participants, and placebo group (n = 18)
with 10 females’ participants. No differences were noticed concerning
the age and duration of DMT2 between the study and placebo group
(57.58 years ± 6.10 vs 57.06 years ± 6.73; and 72.95 months ±
47.57 vs 74.67 months ± 55.75, respectively). Concerning the base-
line anthropometric characteristics at the beginning of the study, no
significant differences existed between the groups (Table 1).
3.2. Anthropometric and clinical parameters
Eight weeks’ treatment with pomegranate peel extract (PoPEx
group) did not have any significant effect on anthropometric para-
meters such as BMI, weight, fat mass and fat free mass. However, it had
a significant effect on reduction of waist circumference (−2.46 cm).
The intake of pomegranate peel extract induced the significant lowering
of both systolic and diastolic blood pressure by 6.06 mmHg and
2.10 mmHg (4.45% and 2.53%), respectively. No such differences were
observed in the placebo group (Table 1). Analysis of energy intake
showed no significant differences in baseline energy intake between the
PoPEx group and the placebo group and at the end of study (Table1).
3.3. Metabolic parameters
Supplementation with pomegranate peel extract for 8 weeks did not
change total cholesterol and LDL-C plasma level, but it significantly
decreased plasma levels of TG (2.74 ± 2.31 vs 2.33 ± 2.31 mmol/L),
as well as the LDL-C/HDL-C ratio (3.18 ± 1.15 vs 2.41 ± 0.90), and
lipid peroxidation index (TBARS; 1.66 ± 0.34 vs 0.40 ± 0.17). At the
same time, plasma level of HDL-C was significantly increased in study
group (1.13 ± 0.25 vs 1.36 ± 0.23 mmol/L; Table 2). Those differ-
ences in metabolic parameters were not observed in the placebo group.
At the end of study, there were no differences between the study and
placebo groups concerning fasting blood glucose, serum insulin con-
centration, and insulin sensitivity, but 8 weeks’ pomegranate peel ex-
tract supplementation significantly decreased HbA1c in study group
(7.65 ± 1.16 vs 7.44 ± 1.09%) (Table 2).
Table 3 displays fatty acids profile in total plasma lipids, in subject
with DMT2, before and after the study period. The results show that
pomegranate peel extract decreased levels of palmitic (16:0) and stearic
acid (18:0) and total saturated fatty acids, after 8 weeks of supple-
mentation (p < 0.05, p < 0.05, p < 0.01 respectively). Also, the
level of arachidonic acid (AA)20 20:4n-6, was significantly higher in the
PoPEx group at the end of study (p < 0.05). Furthermore, some
change in FA composition in subjects who received placebo was ob-
served. Thus, level of stearic acid was significantly lower (p < 0.05) in
the control group. No changes in FA profiles were found in the placebo
group after the treatment.
4. Discussion
The main purpose of the present study was to investigate whether 8-
week long PoPEx consumption could attenuate changes in lipid profile,
fatty acids and blood pressure in subjects with diabetes mellitus type 2.
To the best of our knowledge, the beneficial effects of pomegranate peel
extract have not been studied in DMT2 patients.
In the first step, we made a dry pomegranate peel extract that was
obtained in a ratio 8:1 (peel: extract). During the capsule formulation,
determination of adequate dosage was guided by the World Health
Organization monograph in which the oral daily dose is from 2.5 to
4.5 g (WHO, 2009). Considering that we want to achieve a therapeutic
effect, we opted for a dose of 500 mg per day.
Our findings clearly demonstrated that the consumption of PoPEx
significantly decreased systolic and diastolic BP in patients with DMT2,
compared to the placebo group. The previous studies reported similar
blood pressure-lowering effect of pomegranate juice on diabetic pa-
tients, hypertensive patients, and also on healthy adults (Asgary et al.,
2013; Lynn, Hamadeh, Leung, Russell, & Barker, 2012; Sohrab et al.,
2019). Stockton, Farhat, McDougall, and Al-Dujaili (2017) reported
that 8-week long administration of concentrated extract of whole po-
megranate induced a significant decrease in diastolic BP, but a non-
significant decrease in systolic BP in healthy adults. Several mechan-
isms have been suggested for blood pressure-lowering effect of pome-
granate juice21 (PJ). According to Aviram and Dornfeld (2001), Dos
Santos et al. (2016) polyphenols from pomegranate reduce angiotensin
converting enzyme. Also, pomegranate juice might exert beneficial ef-
fect on vasodilatation of blood vessels promoting Nitric oxide22 (NO)
synthase bioactivity and thus increasing bioavailability of NO
(Sahebkar et al., 2017).
The results of the present study showed no significant interaction
between the consumption of PoPEx and body weight, body fat mass and
fat free mass. Results of previous studies are not consistent (González-
Ortiz, Martínez-Abundis, Espinel-Bermúdez, & Pérez-Rubio, 2011;
Hosseini, Saedisomeolia, Wood, Yaseri, & Tavasoli, 2016; Sohrab et al.,
2019; Stockton et al., 2017). Furthermore, we found a significant de-
crease in WC in PoPEx group. Waist circumference is independent
predictive factor of the chronic disease including diabetes mellitus type
2 (Amato, Guarnotta, & Giordano, 2013). DMT2 risk can decrease when
WC was modified no matter whether BMI remains the same (Luo et al.,
2013). This finding may provide an interesting avenue for further re-
search.
Glycemic control reminds a constant challenge for diabetic patients.
Poor glycemic management is still one of the major causes long-term
adverse outcomes such as macro- and microvascular complication in
DM subject (International Diabetes Federation, 2017). We observed
that administration of PoPEx significantly decreased level of HbA1c, but
exerted no significant change concerning fasting blood glucose, serum
insulin concentration, and insulin sensitivity. Similar results according
mean glycemia were obtained after 30 days’ supplementation of
19 TBARS, Thiobarbituric acid reactive species.
20 AA, arachidonic acid.
21 PJ, pomegranate juice.
22 NO, nitric oxide.
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Table 1
The anthropometric characteristics of Diabetes mellitus Type 2 patients, and responsiveness to pomegranate peel extract and placebo after the 8 weeks’ treatment.
Parameter PoPEx group (n = 19) Placebo group (n = 18)
Before treatment After treatment Before treatment After treatment
BMI (kg/m2) 31.82 ± 4.94 31.94 ± 4.90 32.51 ± 4.72 32.58 ± 4.76
Waist circumference 109.48 ± 10.13 107.02 ± 10.03*** 109.60 ± 10.70 108.98 ± 11.06
Weight (kg) 93.81 ± 16.36 94.20 ± 15.83 95.08 ± 17.05 95.30 ± 17.18
Fat mass (%) 31.73 ± 6.85 31.49 ± 7.07 32.33 ± 8.63 32.38 ± 9.23
Fat free mass (%) 65.25 ± 6.23 65.61 ± 6.51 64.48 ± 8.36 64.31 ± 8.41
Energy intake (kcal) 2274.58 ± 303.57 2301.89 ± 310.13 2273.56 ± 380.96 2282.28 ± 380.74
Systolic BP (mmHg) 136.32 ± 19.57 130.26 ± 14.58** 139.44 ± 14.54 141.94 ± 15.35
Diastolic BP (mmHg) 82.89 ± 8.22 80.79 ± 7.32* 84.88 ± 9.52 85.44 ± 7.69
Data are expressed as the mean ± SD; PoPEx, Pomegranate peel extract; BMI, Body mass index; BP, Blood Pressure.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
Table 2
Effects of pomegranate peel extract (PoPEx) and placebo treatment on metabolic parameters in patients with Diabetes mellitus Type 2.
Parameter PoPEx group (n = 19) Placebo group (n = 18)
Before treatment After treatment Before treatment After treatment
Total Cholesterol mmol/L 5.22 ± 1.20 5.02 ± 1.32 5.43 ± 0.71 5.41 ± 0.74
HDL-C mmol/L 1.13 ± 0.25 1.36 ± 0.23*** 1.08 ± 0.28 1.13 ± 0.30
LDL-C mmol/L 3.44 ± 0.98 3.19 ± 1.13 3.73 ± 0.64 3.74 ± 0.71
TG mmol/L 2.74 ± 2.31 2.33 ± 2.31** 2.13 ± 1.20 2.11 ± 0.87
LDL-C/HDL-C 3.18 ± 1.15 2.41 ± 0.90*** 3.66 ± 1.00 3.53 ± 1.02
FBG mmol/L 9.1 ± 2.10 8.99 ± 2.48 8.57 ± 2.61 8.61 ± 2.40
HbA1c % 7.65 ± 1.16 7.44 ± 1.09* 7.44 ± 1.10 7.41 ± 1.09
Insulin µIU/mL 12.06 ± 6.47 11.74 ± 6.44 14.43 ± 6.75 13.72 ± 5.84
QUICKI index 0.31 ± 0.02 0.31 ± 0.02 0.31 ± 0.03 0.31 ± 0.02
HOMA-IR 4.84 ± 2.90 6.70 ± 1.96 5.32 ± 3.65 5.14 ± 2.93
TBARS mmol/L 1.66 ± 0.34 0.40 ± 0.17*** 1.54 ± 0.12 1.41 ± 0.14
Data are expressed as the mean ± SD. PoPEx, Pomegranate peel extract; HDL-C, High-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol;
TG, triglycerides; FBG, fasting blood glucose; QUICKI index, Quantitative insulin sensitivity check index; HOMA-IR, Homeostatic model of insulin resistance; TBARS,
Thiobarbituric acid reactive substances.
* p < 0.05.
** p < 0.01.
*** p < 0.001.
Table 3
Effects of pomegranate peel extract (PoPEx) and placebo treatment on plasma fatty acids composition (% of total fatty acids) in patients with diabetes mellitus type 2.
Fatty acids PoPEx group (n = 19) Placebo group (n = 18)
Before treatment After treatment Before treatment After treatment
SFA 43.22 ± 1.14 41.84 ± 1.49** 42.66 ± 1.36 42.11 ± 1.34
16:0 30.37 ± 1.71 29.79 ± 1.80* 29.18 ± 1.25 28.55 ± 1.42
18:0 12.85 ± 1.31 12.05 ± 1.31** 13.48 ± 0.83 13.56 ± 0.76*
MUFA 14.78 ± 1.59 15.33 ± 2.41 15.50 ± 1.42 16.04 ± 2.15
16:1 1.07 ± 0.42 1.08 ± 0.36 1.17 ± 0.43 1.23 ± 0.53
18:1n-7 1.17 ± 0.36 1.24 ± 0.25 1.65 ± 0.40 1.72 ± 0.65
18:1n-9 12.54 ± 1.44 13.00 ± 2.11 12.67 ± 1.48 13.08 ± 1.88
PUFA 42.03 ± 2.01 42.83 ± 2.24 41.84 ± 1.77 41.85 ± 2.38
18:2 23.87 ± 3.42 23.67 ± 3.26 23.59 ± 2.54 23.38 ± 3.06
18:3n-3 0.15 ± 0.05 0.27 ± 0.37 0.18 ± 0.09 0.19 ± 0.14
18:3n-6 0.25 ± 0.12 0.25 ± 0.14 0.20 ± 0.10 0.21 ± 0.09
20:3 2.44 ± 0.58 2.46 ± 0.68 2.91 ± 0.80 3.02 ± 0.64
20:4 11.15 ± 2.34 11.99 ± 2.48* 10.79 ± 2.18 10.80 ± 2.03
20:5 0.26 ± 0.17 0.28 ± 0.18 0.40 ± 0.35 0.44 ± 0.28
22:4 1.40 ± 0.43 1.45 ± 0.50 1.01 ± 0.61 1.09 ± 0.58
22:5 0.49 ± 0.19 0.48 ± 0.11 0.49 ± 0.13 0.53 ± 0.14
22:6 2.03 ± 0.69 1.98 ± 0.54 2.26 ± 0.52 2.19 ± 0.54
n-3 2.93 ± 0.93 3.01 ± 0.97 3.34 ± 0.88 3.35 ± 0.83
n-6 39.10 ± 2.21 39.82 ± 2.37 38.50 ± 1.98 38.50 ± 2.59
Data are expressed as the mean ± SD. PoPEx, Pomegranate peel extract; SFA, Saturated fatty acids; MUFA, Monounsaturated fatty acids; PUFA, Polyunsaturated
fatty acids.
* p < 0.05.
** p < 0.01.
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pomegranate extract in overweight and obese participants (Hosseini
et al., 2016). Our finding is not in line with other studies that reported
no changes in long-term glycemic control after administrated pome-
granate juice (González-Ortiz et al., 2011; Huang, Liao, Chen, Chen, &
Zhu, 2017; Sumner et al., 2005). The lack of PoPEx activity on fasting
blood glucose level and serum insulin concentration in our study could
be explained by the fact that all studied individuals were DMT2 patients
on regular metformin therapy; therefore, the glycemic control had been
already established. Glycated protein HbA1c is considered as the stan-
dard measure of long-term glycemic control, and does not reflect gly-
cemic variability. However, HbA1c is strongly associated with compli-
cation of diabetes (Huang et al., 2017). Increase in 1% of the level of
HbA1c is associated with 7.5% increase in cardiovascular disease risk in
DMT2 subjects (Juutilainen, Lehto, Rönnemaa, Pyörälä, & Laakso,
2008). Encouraging findings from animal studies suggested that po-
megranate peel polyphenols could improve glycemic metabolism and
ameliorate insulin sensitivity. It has been suggested that administration
of PoPEx might have hypoglycemic effect by inhibiting activities of α-
glucosidase and α-amylase (Arun, Jayamurthy, Anusha, Mahesh, &
Nisha, 2017; Middha, Usha, & Pande, 2014).
Dyslipidemia is typical feature of DMT2 and is characterized by
elevated TG and LDL-C level, and low level of HDL-C (Matheus et al.,
2013). The characteristic lipid changes are present also in patients with
metabolic syndrome, implicating that disturbed lipid transport in dia-
betic patients is a result of insulin resistance, rather than hyperglycemia
(Parhofer, 2015). The results of the present study clearly demonstrated
that 8-week consumption of pomegranate peel extract induced statis-
tically significant lipid profile improvement. The PoPEx group had
significantly reduced the plasma level of TG and the ratio of LDL-C/
HDL-C, and significantly increased of HDL-C level. These outcomes are
relatively in agreement with previous studies (Esmaillzadeh et al.,
2004; Fenercioglu et al., 2010) who used pomegranate juice supple-
mentation. Furthermore, some studies have reported that pomegranate
polyphenols did not have any significant effect on lipid profile
(Manthou et al., 2017; Sohrab et al., 2019). Discrepancies between
results of different trials could be explained by several reasons: small
sample size, different duration of supplementation period, dose and
form of pomegranate used (Sahebkar, Simental-Mendía, Giorgini, Ferri,
& Grassi, 2016).
Previous in vivo and in vitro studies suggested that extracts of dif-
ferent pomegranate fraction regulate lipid metabolism in metabolic
disorder-associated diseases (Manthou et al., 2017). Some authors have
indicated that pomegranate peel polyphenols, and their main compo-
nents punicalagin and ellagic acid had lipid lowering effect in dose-
dependent manner. The molecular mechanism may consist of the acti-
vation peroxisome proliferator-activated receptor23 γ (PPARγ) and the
enhanced cholesterol metabolism in LO2 cells (Lv, Wang, Li, Ma, &
Zhao, 2016).
Plasma TBARS levels are frequently used marker of lipid peroxida-
tion. A positive effect of PoPEx treatment on lipid peroxidation resulted
in the significant reduction in TBARS levels by 75%. This result is in
line with previous reported in healthy, DM and metabolic syndrome
subject (Aviram et al., 2000; Kojadinovic et al., 2017; Rosenblat et al.,
2006). Studies have reported that PoPEx had significantly higher anti-
oxidative efficacy than the pulp, seed or juice extract (Orak, Yagar, &
Isbilir, 2012; Orgil et al., 2014) in scavenging capacity against hy-
droxyl, superoxide anion and peroxyl radicals, thus exhibiting protec-
tive effects against methotrexate induced oxidative stress and lipid
changes in rats (Doostan et al., 2017).
The 8-week treatment with PoPEx induced marked changes in FA
composition of plasma lipids. The intervention group had significantly
lower levels of individual SFA – palmitic and stearic acid, as well as
total SFA. Saturated fats, in particular palmitic acid, have traditionally
been considered proatherogenic (Micha & Mozaffarian, 2010; Vučić
et al., 2015). Epidemiological studies have demonstrated a positive
correlation between SFA intake and level of LDL-cholesterol (Lefevre,
Champagne, Tulley, Rood, & Most, 2005; van Dijk et al., 2009). The
atherogenic and thrombogenic potential of SFA is exerted through
elevated production of very low density lipoprotein24 (VLDL) particles
and ApoA1, increased platelet aggregation, with decreased specific
activity of LDL-receptors (Iggman & Risérus, 2011). Moreover, it has
been documented that palmitic acid increases insulin resistance, thus
worsening DMT2. Namely, SFA activate serine kinases, thereby in-
hibiting insulin-phosphorylation cascade, diminishing glucose uptake
and increasing level of blood glucose (Hotamisligil, 2006). Palmitic acid
also activates protein kinase C that leads to a higher insulin resistance
and reduced glucose uptake by skeletal muscle cells (Snook, Park,
Williams, Tsai, & Lee, 1999). However, all these effects are mostly at-
tributed to palmitic acid rather than to stearic acid. Consumption of
PoPEx significantly reduced proportions of all SFA, indicating anti-
atherogenic and cardioprotective effects of pomegranate peel extract in
patients with DMT2. It has been shown that punicic acid found in po-
megranate, can bind and activate PPAR α, thus upregulating PPAR α
and its responsive genes, among them Stearoyl-CoA desaturase-125
(SCD-1) (Viladomiu, Hontecillas, Lu, & Bassaganya-Riera, 2013). The
decrease in the level of SFA may result from increased activity of SCD-1
that leads to an increased synthesis of monounsaturated FA. Our study
showed an increase in both oleic and vaccenic acids after consumption
of pomegranate peel pills, but these changes are not significant.
Nevertheless, we found no significant increase in oleic and vaccenic
acids after consumption of pomegranate peel pills, that could be due to
a limited length of this study.
Besides SFA, PoPEx treatment induced an increase in AA as well.
Arachidonic acid is a precursor for a wide spectrum of potent proin-
flammatory eicosanoids, including prostaglandins series 2 and leuko-
triens series 4 (Innes & Calder, 2018; Ristic-Medic, Vucic, Takic,
Karadžic, & Glibetic, 2013), and high levels of AA have often been
found in inflammatory states. However, an increase of AA in plasma
lipids of patients with DMT2 who consumed PoPEx, has not been fol-
lowed by a decrease in its precursor linoleic acid26 (LA, 18:2n-6) sug-
gesting that PoPEx had no effect on conversion of LA to AA, but rather
that conversion of AA to eicosanoids was inhibited. Therefore, we can
speculate that intake of PoPEx diminished inflammation in DMT2 pa-
tients, which is in line with decreased levels of interleukin 627 (IL-6) in
these patients (Shishehbor et al., 2016). The mechanism of action of
PoPEx could also be attributed to punicic acid, which binds PPARs.
PPARs are the receptors for endogenous lipid molecules (i.e., pros-
taglandins or hydroxy-containing PUFA) and molecular targets for
drugs against type 2 diabetes (Mokdad et al., 2001). They also represent
promising new targets for the treatment and prevention of in-
flammatory disorders (Dubuquoy et al., 2003; Katayama et al., 2003).
Namely, punicic acid activate PPAR thereby inhibiting generation of
prostaglandins and diminishing inflammation, with concomitant accu-
mulation of AA.
Alterations in FA profiles in the intervention group led to decreased
n-6/n-3 PUFA ratio, which is an important inflammatory marker. The
World Health Organization28 (WHO) recommended the ratio in the diet
of 4:1. However, in most Western diets this ratio is 15–20:1 (Burdge &
Calder, 2006). Wall, Ross, Fitzgerald, and Stanton (2010) have re-
viewed that lowering this ratio in the diet may reduce the incidence of
several chronic inflammatory diseases, such as CVD, autoimmune dis-
eases, as well as psychiatric and neurodegenerative illnesses.
23 PPAR, peroxisome proliferator-activated receptor.
24 VLDL, very low density lipoprotein.
25 SCD-1, stearoyl-CoA desaturase-1.
26 LA, linoleic acid.
27 IL-6, interleukin 6.
28 WHO.
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5. Conclusion
The present study clearly demonstrated that 8-weeks supple-
mentation with pomegranate peel extract attenuated the systolic and
diastolic blood pressure in patients with type 2 diabetes. This treatment
has also shown its beneficial effects on blood levels of TG, HDL-C,
TBARS, HbA1c and fatty acids profile in total plasma lipids of these
patients, suggesting on hypolipaemic, hypoglycemic, and antioxidative
potential of pomegranate peel extract. Further studies are needed in
order to get deeper insights of molecular mechanisms underlying these
very complex effects of pomegranate peel poyphenols on glucose and
lipid metabolism pathways in metabolic disorders.
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